ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 1588

Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia

Julia Tan1, J. Antonio Avina-Zubieta2, Alyssa Dominique3, Hamid Tavakoli4 and Teresa A Simon3, 1Medicine, University of British Columbia, Vancouver, BC, Canada, 2Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, 3Bristol-Myers Squibb, Princeton, NJ, 4Arthritis Research Canada, Vancouver, BC, Canada

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: Malignancy, population studies, psoriasis and psoriatic arthritis

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriasis (PsO) is a relapsing chronic autoimmune disease of the skin. Up to one-third of patients (pts) also develop inflammatory arthritis, known as psoriatic arthritis (PsA). PsO/PsA, like other forms of chronic inflammatory arthritis, are often associated with complications such as cardiovascular disease and infections. However, data on the risk of cancer in pts with PsO/PsA at population level are limited.

Methods: We created a population-based matched retrospective cohort of PsO/PsA pts diagnosed between 1 January 1997 and 31 December 2012 using administrative health data from British Columbia, Canada. We identified all incident cases of PsO/PsA and an equal number of controls matched on sex, age and calendar year. PsO/PsA cases met ≥1 of the following: 1 diagnostic code for PsO/PsA by a rheumatologist/dermatologist; ≥2 diagnostic codes for PsO/PsA, ≥2 months apart in a 2-year period by a non-rheumatologist/dermatologist; or ≥1 hospitalization with diagnostic code for PsO/PsA. We evaluated incident cancers during follow-up from the Cancer Registry in both cohorts. Adjusted risk of cancers was estimated using a generalized estimating equation extension of multivariate Poisson regression models.

Results: We identified 81,568 incident cases of PsO/PsA (mean age 48.5 years [SD=17.8], 51.5% female). Individuals with PsO/PsA were at significantly higher risk of being diagnosed with 8/41 types of cancer examined, including eye and orbit (4 fold), female genital (3 fold), non-melanoma skin (2 fold), prostate (males; 1.1 fold) (Table). Incidence of rectum and colon cancer was lower among PsO/PsA pts relative to the non-PsO/PsA cohort (Table)

Conclusion: This general population-based study demonstrates that pts with PsO/PsA have an increased risk of several types of cancer, and a decreased risk of rectum and colon cancer. This association highlights the need to further explore potential risk factors and pathways that contribute to these complications.

Outcome

PsO/PsA events

Non-PsO/PsA events

PsO/PsA follow-up (PY)

Non-PsO/PsA follow-up (PY)

PsO/PsA IR (per 100,000 PY)

Non-PsO/PsA IR (per 100,000 PY)

IRR
(95% CI)

Eye and orbit

13

<5

623,843.5

<5

2.08

–

4.25
(1.21, 14.91)

Female genital other than cervix uteri, corpus uteri and ovary

55

21

623,625.8

611,542.1

8.81

3.43

2.57
(1.55, 4.25)

Other urinary

31

16

623,818.6

611,585.4

4.97

2.62

1.90
(1.04, 3.47)

Non-melanoma skin

401

217

621,233.8

610,223.9

64.54

35.56

1.82
(1.54, 2.14)

Lung

705

589

622,877.2

610,834.8

113.18

96.42

1.17
(1.05, 1.31)

Prostate

760

664

620,065.8

608,124.9

122.57

109.19

1.12
(1.01, 1.25)

Melanoma

218

200

622,791

610,672.1

35.0037

32.7508

1.07

Colon

286

332

622,845.1

610,410.5

45.91

54.39

0.84
(0.72, 0.99)

Rectum

157

194

623,196.9

610,811.7

25.19

31.76

0.79
(0.64, 0.98)

IRR=incidence rate ratio; PY=patient years


Disclosure: J. Tan, None; J. A. Avina-Zubieta, Bristol-Myers Squibb, 2; A. Dominique, Bristol-Myers Squibb, 3; H. Tavakoli, None; T. A. Simon, Bristol-Myers Squibb, 3.

To cite this abstract in AMA style:

Tan J, Avina-Zubieta JA, Dominique A, Tavakoli H, Simon TA. Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/risk-of-cancer-in-patients-with-psoriasis-psoriatic-arthritis-a-population-based-study-in-the-province-of-british-columbia/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2018

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-cancer-in-patients-with-psoriasis-psoriatic-arthritis-a-population-based-study-in-the-province-of-british-columbia/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology